Robert F. Kennedy Jr. Leadership Creates Environment Challenging Vaccine Development
State Secretary Marco Rubio revealed the State Department was taking control of vaccine development and distribution from RFK Jr. as Ebola spreads
Objective Facts
On June 2, 2026, State Secretary Marco Rubio revealed to the Senate Foreign Relations Committee that he was planning to take the reins on vaccine development and distribution from Kennedy as the Ebola virus spreads. Congress appropriated $300 million each for fiscal 2025 and 2026 to Gavi, which Kennedy has blocked. HHS said it was withholding funding in part because Gavi declined to develop a plan to phase out vaccines containing thimerosal, a preservative Kennedy believes likely causes autism. More broadly, Kennedy's appointment as health secretary sparked concerns among public health experts, and those fears are beginning to come true according to vaccine executives and investors, with vaccine makers investing less in research and development. Kennedy announced $500 million in mRNA vaccine development projects using technology developed by leading companies like Pfizer and Moderna will be halted.
Left-Leaning Perspective
The Center for American Progress reported that in early June, more than 6,000 health care professionals signed an open letter warning the public that their health is at risk due to severe cuts and dismantling of programs designed to promote and protect health under Kennedy's leadership. The Center detailed that Kennedy altered research priorities at the NIH by canceling studies on mRNA vaccines and vaccine hesitancy, and hired David Geier, a known vaccine skeptic disciplined for practicing medicine without a license, to lead a study reinvestigating the vaccine-autism theory. BioPharma Dive quoted Jeff Coller from Johns Hopkins saying mRNA made 9-month vaccine development 'never happened in human history,' adding it's 'absolutely perplexing' why Trump would allow Kennedy to undermine life-saving therapeutics. Senator Elizabeth Warren criticized Kennedy at his confirmation hearing, stating that as HHS secretary he will have power to undercut vaccines and vaccine manufacturing, and 'Kennedy can kill off access to vaccines and make millions of dollars while he does it'. ProPublica reported Kennedy has the power to drop vaccines from the list, opening manufacturers to lawsuits, with one former Merck vaccine executive warning 'if his unstated goal is to basically destroy the vaccine industry, that could do it'. Criticisms emphasize the broader chilling effect: Jeff Coller said Kennedy's changes 'sent a chill through the entire industry'. Left-leaning coverage omits or downplays any legitimate vaccine safety concerns that motivated Kennedy's appointments or policy shifts, focusing instead on his prior anti-vaccine advocacy and framing all actions as ideologically driven rather than science-based.
Right-Leaning Perspective
Fox News reported that Kennedy fired all existing vaccine panel members, saying this was necessary to restore public trust and reduce conflicts of interest, with the panel reconstituted with appointees 'aligned with his views on vaccine safety, transparency and scientific rigor'. Fox quoted Kennedy directly: 'We reviewed the science, listened to the experts, and acted,' adding that mRNA vaccines 'fail to protect effectively against upper respiratory infections like COVID and flu' and HHS is 'shifting that funding toward safer, broader vaccine platforms'. However, even Republican Senator Bill Cassidy challenged Kennedy's approach, noting he believed Trump deserved credit for Operation Warp Speed developing COVID vaccines, then questioning why Kennedy canceled $500 million in mRNA contracts under that same platform. The Washington Post noted that some Republicans warned any more vaccine policy changes could damage the party in the midterms. MSNBC analysis found that Fox News has almost entirely ignored Kennedy's termination of $500 million in mRNA funding, suggesting right-leaning media provided limited scrutiny of Kennedy's vaccine development decisions despite Republican senators raising concerns. Right-wing coverage largely amplified Kennedy's framing of changes as safety-focused rather than examining the market impact on vaccine development.
Deep Dive
When Kennedy was nominated as health secretary in November 2024, public health experts worried the longtime vaccine skeptic would wreak havoc on vaccine development, and by February 2026 those fears were realized—Moderna pulling back vaccine studies in Massachusetts, a Texas company canceling factory expansion, and San Diego manufacturers laying off workers. The development freeze creates two concurrent crises: immediate (blocking $600 million in emergency Gavi funds during active Ebola outbreak) and long-term (halting $500 million in mRNA platform research). The angle of the story centers on how Kennedy's leadership created an environment where vaccine development itself became challenging—the U.S. contributed about 13 percent of Gavi's budget until June 2025 when Kennedy decided vaccine development would no longer be HHS's priority. What each perspective gets right: Left-wing critics accurately identify that Kennedy's actions—firing ACIP members, blocking publications, withholding congressional appropriations—have had measurable chilling effects on investment and research momentum. Even some Republicans acknowledged the problem, with some warning that vaccine policy changes could damage the party in midterms. Right-leaning framing correctly notes Kennedy's concern about vaccine transparency and safety monitoring. What's omitted from each: Left coverage rarely acknowledges legitimate questions about accelerated vaccine approval timelines or existing safety monitoring gaps; conservative coverage downplays the market-driven reality that vaccine manufacturers will exit markets when profit margins don't justify liability risks. The June 2 Rubio intervention signals internal Trump administration conflict, with Rubio stating the State Department would 'reengage' on Gavi while still 'listening to Kennedy's points of view,' but making clear the State Department will take the lead. Watch for: (1) Whether Trump administration releases the $600 million in blocked Gavi funds before September 30 expiration; (2) Whether Ebola vaccine development timelines slip due to delays; (3) Whether vaccine manufacturers continue reducing U.S. research or exit markets entirely; (4) Congressional action to restore mRNA development funding.